-

Update on 92nd Vifor Pharma Ltd. Annual General Meeting

  • AGM will take place as planned on 14 May, 2020 under extraordinary conditions
  • Shareholders are not allowed to attend in person and are requested to vote via independent proxy

ST GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News:

Vifor Pharma confirmed that it will hold its Annual General Meeting (AGM) on 14 May, 2020, as planned. In view of the current situation and based on Art. 6a of Ordinance 2, issued by the Swiss Federal Council, regarding measures against combatting the coronavirus (COVID-19), shareholders will not be allowed to attend the event in person. In addition, the AGM will not include an address by the Executive Chairman, senior management or a webcast.

At Vifor Pharma the health of shareholders and employees is a priority, therefore the Board of Directors has decided that shareholders will be able to exercise their rights at the General Meeting exclusively through the independent proxy. By following this measure, Vifor Pharma will ensure that the Annual General Meeting can be held on the originally scheduled date.

The voting results will be published on https://www.viforpharma.com/en/investors/shareholders-information/annual-general-meeting shortly after the AGM.

Vifor Pharma Group is a global specialty pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com

Contacts

Media Relations
Nathalie Ponnier
Global Corporate Communications
+41 79 957 96 73
media@viforpharma.com

Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com

Industry:

Vifor Pharma

SWX:VIFN
Release Versions
EnglishGermanFrench

Contacts

Media Relations
Nathalie Ponnier
Global Corporate Communications
+41 79 957 96 73
media@viforpharma.com

Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com

Social Media Profiles
Vifor Pharma
More News From Vifor Pharma

Cancellation of remaining publicly held registered shares of Vifor Pharma AG

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each (each a "Vifor Share"). The Commercial Court's decision has become legally effective (rechtskräftig) and is published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblat...

Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients

ST. GALLEN, Switzerland & BEIJING--(BUSINESS WIRE)--Regulatory News: CSL Vifor and Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject®, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly. Ferinject® has now received marketing authorization...

Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: Tomorrow is Iron Deficiency Day. For the eighth consecutive year, CSL Vifor is supporting a growing alliance of international organizations including the Heart Failure Policy Network, European Kidney Health Alliance, Global Heart Hub and Croí the West of Ireland Cardiac Foundation to advocate people at risk to listen to their body, to take iron seriously and to take control over their health by seeking early diagnosis and medical help f...
Back to Newsroom